MFG
MYGN icon

Menard Financial Group’s Myriad Genetics MYGN Stock Holding History

Menard Financial Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,165
Closed -$16K – 235
2024
Q4 		$16K Buy
+1,165
New +$21.5K 0.01% 219

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Menard Financial Group's MYGN Position: Q1 2025 in Review

Menard Financial Group sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 1,165 shares — an estimated $16K sold.

Menard Financial Group first reported a position in MYGN in Q4 2024 and held it in 1 quarter. The position peaked at $16K in Q4 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

  • Menard Financial Group reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
  • Menard Financial Group sold 1,165 Myriad Genetics shares in Q1 2025, an estimated $16K.
  • Menard Financial Group first reported a position in Myriad Genetics in Q4 2024 and held it in 1 quarter.
  • Menard Financial Group's Myriad Genetics position peaked at $16K in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on Menard Financial Group's 13F filing for Q1 2025, filed 8 May 2025.